Embla Medical Completes Majority Share Acquisition of Streifeneder ortho.production

Embla Medical Finalizes Majority Share Investment in Streifeneder ortho.production

Embla Medical hf, a prominent provider of innovative mobility solutions, has officially closed its transaction to acquire a majority share in Streifeneder ortho.production GmbH. This landmark investment, completed on August 29, 2025, marks a significant milestone in Embla's commitment to expanding its portfolio of orthopedic mobility solutions.

Streifeneder ortho.production, known for its development and supply of orthopedic mobility solutions, boasts a workforce of around 100 employees. In the previous fiscal year, the company reported sales figures of approximately EUR 25 million (around USD 29 million), with an impressive 70% of that revenue generated from prosthetic and orthopedic materials. This acquisition not only bolsters Embla Medical's market presence but also aims to enhance the integration of various mobility solutions offered across their global network.

Upon completing this acquisition, Embla Medical now holds a 51% ownership stake in Streifeneder ortho.production, following the necessary regulatory approvals. This move aligns with Embla's strategic vision to further innovate within the orthopedic sector, leveraging Streifeneder's established reputation.

In accordance with the investment, Embla Medical's Board of Directors has approved a share issuance aimed at funding the acquisition. They plan to issue 2,805,135 new shares at a price of DKK 33.26 each, thereby increasing the total share capital by 0.7%, from ISK 427,636,122 to ISK 430,441,257. The total inflow from this share issuance is projected to raise DKK 93 million (approximately EUR 12.5 million). The sellers of Streifeneder will subscribe to all new shares, which comes with a two-year lock-up period following the transaction's closure.

Despite the scale of this transaction, Embla Medical does not anticipate it will materially impact their financial forecasts for 2025. This strategic acquisition reflects Embla’s ongoing commitment to improving mobility solutions and underscores their dedication to developing and enhancing products that positively impact the health and well-being of individuals worldwide.

Founded in 1971 in Reykjavik, Embla Medical has evolved into a key player in the global orthopedic industry, representing notable brands like Össur, FIOR GENTZ, and College Park Industries. Their extensive network across Orthotic and Prosthetic (OP) facilities globally enables Embla to provide world-class care to patients while maintaining their commitment to sustainable practices in alignment with the United Nations’ Global Compact and Sustainable Development Goals.

With over 4,000 employees, Embla Medical is poised to continue expanding its reach in the orthopedic sector through strategic alliances like this one with Streifeneder ortho.production. As the demand for innovative mobility solutions continues to grow, Embla Medical remains focused on enhancing product offerings and improving patient outcomes globally.

For further developments and information, stakeholders and interested parties can keep an eye on Embla Medical's official communications and the latest press releases.